Positron Emission Tomography (PET) imaging of neurodegenerative biomarkers in people ‘at risk’ for dementia

The University of Sydney0 个研究点目标入组 82 人开始时间: 2022年2月14日最近更新: 2022年2月21日

适应症

试验速览

暂无简介。

•1.Adults aged between 50 and 90 years
•2.Referred due to concerns about new onset of mood or cognitive problems (within the last 5-years) that are not due to other medical conditions
•3.A MMSE score of greater than or equal to 20 (a widely used screening tool).
•4.Willingness to give written informed consent and willingness to participate and comply with the study.
•5.Have undergone the full Healthy Brain Ageing clinic assessment protocol including the collection of blood for genotyping.
•6.Willing to undergo PET scanning within one month of Healthy Brain Ageing clinic assessment.
•7.Subject to available funding.
•8.Considered appropriate candidate by the treating clinician.

•1.Prior head injury (with loss of consciousness of greater than 30min)
•3.Major non-affective mental health disorder such as schizophrenia, Bipolar Disorder, ADHD, Autism, PTSD, chronic fatigue syndrome or acute psychosis
•4.Major neurological condition such as Parkinson’s disease, epilepsy
•5.Current or past alcohol or substance misuse
•6.Intellectual disability
•7.Currently taking benzodiazepines
•8.Currently taking antipsychotics
•9.Currently consuming more than 14 standard drinks of alcohol per week
•10.Females who have not yet undergone menopause
•11.A history of cancer diagnosis within the past 5 years
•12.Current or prior kidney disease or any history of poor renal function that in the opinion of the investigator may deem it unsafe to participate in the study.

发起方